Background

Preventing cancer recurrence remains an unmet clinical need. A cancer peptide vaccine technology, available from HJF for licensing, has shown significant clinical efficacy in preventing and reducing the risk of recurrence of ovarian and endometrial cancers.

Technology Overview

This technology is directed to using a folate binding peptide (FBP)-related cancer vaccine for preventing the recurrence in endometrial and ovarian cancer patients with a high risk of recurrence. Two short peptides, E39 and E39’ are used as vaccine and booster, respectively. Two completed clinical trials, NCT01580696 (phase I/IIa) and NCT02019524 (phase Ib), have shown that this cancer vaccine is efficacious and safe. They were well tolerated and only mild adverse events were observed. A dose regimen for clinical application of